RS58562B1 - Postupak za sterilnu proizvodnju čestica lipid-nukleinska kiselina - Google Patents

Postupak za sterilnu proizvodnju čestica lipid-nukleinska kiselina

Info

Publication number
RS58562B1
RS58562B1 RS20190426A RSP20190426A RS58562B1 RS 58562 B1 RS58562 B1 RS 58562B1 RS 20190426 A RS20190426 A RS 20190426A RS P20190426 A RSP20190426 A RS P20190426A RS 58562 B1 RS58562 B1 RS 58562B1
Authority
RS
Serbia
Prior art keywords
sterilely
nucleic acid
acid particles
producing lipid
lipid
Prior art date
Application number
RS20190426A
Other languages
English (en)
Inventor
Victor Knopov
Richard P Witte
Priya Karmali
Robin Lee
David Webb
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of RS58562B1 publication Critical patent/RS58562B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/04—Making microcapsules or microballoons by physical processes, e.g. drying, spraying
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
RS20190426A 2011-11-04 2012-11-02 Postupak za sterilnu proizvodnju čestica lipid-nukleinska kiselina RS58562B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161556124P 2011-11-04 2011-11-04
PCT/IB2012/002916 WO2013064911A2 (en) 2011-11-04 2012-11-02 Single use system for sterilely producing lipid-nucleic acid particles
EP12829180.4A EP2773326B1 (en) 2011-11-04 2012-11-02 Method for sterilely producing lipid-nucleic acid particles

Publications (1)

Publication Number Publication Date
RS58562B1 true RS58562B1 (sr) 2019-05-31

Family

ID=47178988

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190426A RS58562B1 (sr) 2011-11-04 2012-11-02 Postupak za sterilnu proizvodnju čestica lipid-nukleinska kiselina

Country Status (21)

Country Link
US (1) US8956572B2 (sr)
EP (4) EP2773328A2 (sr)
JP (3) JP6133883B2 (sr)
KR (2) KR102046968B1 (sr)
CN (2) CN103906503B (sr)
AU (2) AU2012356239B2 (sr)
CA (2) CA2853685C (sr)
CY (1) CY1121495T1 (sr)
DK (1) DK2773326T3 (sr)
ES (1) ES2721325T3 (sr)
HR (1) HRP20190481T1 (sr)
HU (1) HUE043809T2 (sr)
LT (1) LT2773326T (sr)
PL (1) PL2773326T3 (sr)
PT (1) PT2773326T (sr)
RS (1) RS58562B1 (sr)
RU (2) RU2647476C2 (sr)
SI (1) SI2773326T1 (sr)
TR (1) TR201904389T4 (sr)
TW (3) TWI618548B (sr)
WO (2) WO2013064911A2 (sr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT3682905T (lt) 2011-10-03 2022-02-25 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai ir nukleorūgštys bei jų naudojimas
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
US9320297B2 (en) 2012-03-22 2016-04-26 Lemniscate Innovations Llc Spherification/reverse spherification automated and integrated system and method
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
PL3489220T3 (pl) 2012-06-08 2021-11-02 Nitto Denko Corporation Lipidy do preparatów do dostarczania środka terapeutycznego
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
AU2014215421A1 (en) 2013-02-05 2015-08-13 1Globe Health Institute Llc Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
SI3019619T1 (sl) 2013-07-11 2021-12-31 Modernatx, Inc. Sestave, ki zajemajo sintetične polinukleotide, ki kodirajo proteine, pozvezane s crispr, in sintetične sgrna, ter metode uporabe
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
CA2921161A1 (en) 2013-09-24 2015-04-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for the manufacture of lipid nanoparticles
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
CN103599549A (zh) * 2013-11-22 2014-02-26 大连民族学院 一种siRNA/抗癌药物联合转运复合载体及其制备方法和应用
AU2015249553B2 (en) 2014-04-23 2021-03-04 Modernatx, Inc. Nucleic acid vaccines
JP6782171B2 (ja) 2014-07-02 2020-11-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド メッセンジャーｒｎａのカプセル化
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
US10342761B2 (en) * 2014-07-16 2019-07-09 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
WO2016045732A1 (en) * 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
AU2015373071B2 (en) * 2014-12-29 2022-03-31 Toray Industries, Inc. Composition containing nucleic acid molecule stably
AU2016222746A1 (en) 2015-02-24 2017-09-07 The University Of British Columbia Continuous flow microfluidic system
CN107921381B (zh) * 2015-04-28 2021-11-09 不列颠哥伦比亚大学 一次性微流控盒
PT3303583T (pt) 2015-05-29 2020-07-07 Curevac Ag Um método para produção e purificação de rna, compreendendendo pelo menos um passo de filtração por fluxo tangencial
PT3324932T (pt) * 2015-07-22 2021-04-06 Nitto Denko Corp Composições e métodos para formas de liófilos de nanopartículas
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
US9938572B1 (en) * 2015-09-08 2018-04-10 Raindance Technologies, Inc. System and method for forming an emulsion
ES2908449T3 (es) 2015-09-17 2022-04-29 Modernatx Inc Polinucleótidos que contienen una región de cola estabilizadora
HUE057613T2 (hu) 2015-09-17 2022-05-28 Modernatx Inc Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
EP3964200A1 (en) 2015-12-10 2022-03-09 ModernaTX, Inc. Compositions and methods for delivery of therapeutic agents
US10799463B2 (en) 2015-12-22 2020-10-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
DK3394093T3 (da) 2015-12-23 2022-04-19 Modernatx Inc Fremgangsmåder til anvendelse af ox40-ligand-kodende polynukleotider
AU2016385135B2 (en) 2016-01-06 2022-02-17 The University Of British Columbia Bifurcating mixers and methods of their use and manufacture
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
SG11201807780XA (en) 2016-03-10 2018-10-30 Lonza Ag Customizable facility
US10689873B2 (en) 2016-03-10 2020-06-23 Lonza Ltd Customizable facility
US20200315967A1 (en) * 2016-06-24 2020-10-08 Modernatx, Inc. Lipid nanoparticles
US11191849B2 (en) 2016-06-30 2021-12-07 Arbutus Biopharma Corporation Compositions and methods for delivering messenger RNA
CN109715782A (zh) * 2016-08-02 2019-05-03 隆扎有限公司 可定制设施
WO2018035388A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
US20200283743A1 (en) 2016-08-17 2020-09-10 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018035476A1 (en) * 2016-08-18 2018-02-22 Troy Bremer Delivery of urea to cells of the macula and retina using liposome constructs
EP3315125A1 (en) * 2016-10-31 2018-05-02 Silence Therapeutics (London) Ltd Lipid nanoparticle formulation
WO2018089540A1 (en) * 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
HRP20230063T1 (hr) 2017-03-15 2023-03-17 Modernatx, Inc. Spoj i pripravci za intracelularnu isporuku terapijskih sredstava
DK3596042T3 (da) 2017-03-15 2022-04-11 Modernatx Inc Krystalformer af aminolipider
US20200405639A1 (en) 2017-04-14 2020-12-31 The Broad Institute, Inc. Novel delivery of large payloads
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
EP3651733A4 (en) * 2017-07-10 2021-04-07 ImmunoVaccine Technologies Inc. PHARMACEUTICAL COMPOSITIONS, METHOD OF MANUFACTURING USING LIPID VESICLE PARTICLES OF DEFINED SIZE, AND USES THEREOF
EP3662913A4 (en) 2017-08-04 2021-06-30 Kyowa Kirin Co., Ltd. LIPID NANOPARTICLES CONTAINING NUCLEIC ACID
JP2019043216A (ja) 2017-08-30 2019-03-22 いすゞ自動車株式会社 ステアリング装置
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
US11395799B2 (en) 2017-10-20 2022-07-26 BioNTech SE Preparation and storage of liposomal RNA formulations suitable for therapy
WO2019088193A1 (ja) * 2017-11-01 2019-05-09 国立大学法人大阪大学 所望の粒径を有する脂質粒子を製造するための方法および装置の開発
WO2019090411A1 (en) * 2017-11-09 2019-05-16 Immmunovaccine Technologies Inc. Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
WO2019204451A1 (en) * 2018-04-17 2019-10-24 Carnegie Mellon University Enhanced lipid nanoparticle drug delivery using a negatively charged polymer
WO2020047061A1 (en) * 2018-08-29 2020-03-05 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
EP3853305B1 (en) 2018-09-19 2024-10-02 ModernaTX, Inc. High-purity peg lipids and uses thereof
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
CN113271926A (zh) * 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
WO2020061426A2 (en) * 2018-09-21 2020-03-26 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
PT3864163T (pt) 2018-10-09 2024-04-30 Univ British Columbia Composições e sistemas que compreendem vesículas competentes para transfeção isentas de solventes orgânicos e detergentes e métodos relacionados com as mesmas
EP3866825A1 (en) * 2018-10-19 2021-08-25 Translate Bio, Inc. Pumpless encapsulation of messenger rna
MX2021009245A (es) * 2019-01-31 2021-11-12 Modernatx Inc Metodos de preparacion de nanoparticulas lipidicas.
US20220177863A1 (en) 2019-03-18 2022-06-09 The Broad Institute, Inc. Type vii crispr proteins and systems
EP3942050A4 (en) * 2019-03-19 2023-02-22 Arcturus Therapeutics, Inc. PROCEDURE FOR THE PRODUCTION OF LIPID-COATED RNA NANOPARTICLES
AU2020269626A1 (en) 2019-05-07 2021-10-28 Universidade Do Minho Method for production of liposomes
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
JOP20220037A1 (ar) 2019-08-14 2023-01-30 Acuitas Therapeutics Inc جسيمات نانوية دهنية محسنة لتوصيل الأحماض النووية
AU2020342668A1 (en) 2019-09-06 2022-03-03 Generation Bio Co. Lipid nanoparticle compositions comprising closed-ended DNA and cleavable lipids and methods of use thereof
JP7271374B2 (ja) * 2019-09-10 2023-05-11 株式会社東芝 分析方法、分析基体、分析キット及び分析装置。
TW202124360A (zh) 2019-09-19 2021-07-01 美商現代公司 用於治療劑之細胞內遞送之支鏈尾端脂質化合物及組合物
EP4061797A1 (en) 2019-11-22 2022-09-28 Generation Bio Co. Ionizable lipids and nanoparticle compositions thereof
KR102409145B1 (ko) * 2020-03-23 2022-06-15 프레스티지바이오로직스 주식회사 항체 의약품 제조 공정을 위한 버퍼 조제 및 이송 시스템
CN111467321A (zh) * 2020-03-26 2020-07-31 深圳市新合生物医疗科技有限公司 一种mRNA核酸类药物胞内递送系统、制备方法和应用
KR20230065281A (ko) 2020-09-13 2023-05-11 아크투루스 쎄라퓨틱스, 인크. 큰 rna의 지질 나노입자 캡슐화
CN112843019A (zh) * 2021-01-27 2021-05-28 江苏普瑞康生物医药科技有限公司 一种核酸脂质纳米粒组合物，包含其的药物制剂，及其制备方法和应用
WO2022177977A1 (en) * 2021-02-16 2022-08-25 The Johns Hopkins University Methods for preparation of plasmid dna/lipid particles with defined size for in vitro and in vivo transfection
WO2022175366A1 (en) 2021-02-17 2022-08-25 Secoya Technologies Method for producing lipid nanoparticles and lipid nanoparticles resulting therefrom
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
US20240165044A1 (en) * 2021-04-22 2024-05-23 Inventage Lab Inc. Lipid nanoparticle preparation method and preparation apparatus therefor
AU2022291742A1 (en) 2021-06-14 2023-12-21 Generation Bio Co. Cationic lipids and compositions thereof
EP4412591A1 (en) * 2021-10-06 2024-08-14 leon-nanodrugs GmbH Method for preparing lipid nanoparticles
AU2022383068A1 (en) 2021-11-08 2024-05-02 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
CN116549626A (zh) * 2022-01-27 2023-08-08 深圳瑞吉生物科技有限公司 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
KR102475540B1 (ko) * 2022-04-26 2022-12-08 주식회사 무진메디 약물이 담지된 지질 나노입자 제조 방법 및 제조 장치
WO2023239756A1 (en) 2022-06-07 2023-12-14 Generation Bio Co. Lipid nanoparticle compositions and uses thereof
WO2024102677A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Circular rna compositions
TW202425959A (zh) 2022-11-08 2024-07-01 美商歐納醫療公司 遞送多核苷酸的脂質及奈米顆粒組合物
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024119051A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
WO2024119103A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
WO2024119039A2 (en) 2022-12-01 2024-06-06 Generation Bio Co. Stealth lipid nanoparticles and uses thereof
WO2024119074A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Stealth lipid nanoparticle compositions for cell targeting
WO2024129982A2 (en) 2022-12-15 2024-06-20 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024136254A1 (ko) * 2022-12-20 2024-06-27 (주)인벤티지랩 저농도 이온화 지질을 포함하는 지질나노입자 및 이의 제조 방법
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01501228A (ja) * 1986-09-18 1989-04-27 リポソーム　テクノロジー，インコーポレイテッド 高濃度リポソーム処理方法
US4781871A (en) * 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US4895452A (en) 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
EP0706374B1 (en) * 1993-06-30 1997-12-10 Genentech, Inc. Method for preparing liposomes
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
CA2222328C (en) 1995-06-07 2012-01-10 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6395302B1 (en) 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
US6287591B1 (en) * 1997-05-14 2001-09-11 Inex Pharmaceuticals Corp. Charged therapeutic agents encapsulated in lipid particles containing four lipid components
EP1146959B1 (en) 1998-11-13 2008-06-04 William A. Heriot Apparatus for liposome production
US6855296B1 (en) 1998-11-13 2005-02-15 Optime Therapeutics, Inc. Method and apparatus for liposome production
US7094423B1 (en) 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
AU769357B2 (en) * 1999-07-15 2004-01-22 University Of British Columbia, The Methods for preparation of lipid-encapsulated therapeutic agents
EP1203614A1 (de) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
ATE381963T1 (de) 2001-10-26 2008-01-15 Octoplus Technologies B V Verfahren zur herstellung von gereinigten partikeln
US7223887B2 (en) 2001-12-18 2007-05-29 The University Of British Columbia Multivalent cationic lipids and methods of using same in the production of lipid particles
EP1471885A4 (en) 2002-01-09 2009-04-22 Transave Inc EFFECTIVE ENCAPSULATION IN A LIPOSOME
US6712963B2 (en) 2002-06-14 2004-03-30 Scilog, Llc Single-use manifold for automated, aseptic transfer of solutions in bioprocessing applications
CA2491164C (en) 2002-06-28 2012-05-08 Cory Giesbrecht Method and apparatus for producing liposomes
FR2856940B1 (fr) * 2003-07-04 2007-02-09 Stedim Sa Systeme clos a usage unique de melange, de stockage et d'homogeneisation de liquides en conditions propres ou steriles
WO2005090403A2 (en) * 2004-03-12 2005-09-29 Biovest International, Inc. Method and apparatus for antibody purification
AU2005250500B2 (en) 2004-06-04 2011-06-23 Global Life Sciences Solutions Usa Llc Disposable bioreactor systems and methods
US7410587B2 (en) 2004-08-03 2008-08-12 Scilog, Inc. Liquid handling for filtration and preparative chromatography
US7404969B2 (en) * 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
AU2006274413B2 (en) 2005-07-27 2013-01-10 Arbutus Biopharma Corporation Systems and methods for manufacturing liposomes
JP5336853B2 (ja) * 2005-11-02 2013-11-06 プロチバ バイオセラピューティクス インコーポレイティッド 修飾ｓｉＲＮＡ分子およびその使用法
CA2649025A1 (en) 2006-04-11 2007-10-18 Wingturf Co., Ltd. Production method of liposome dispersion and production equipment thereof
EP1920765A1 (en) 2006-11-07 2008-05-14 Medigene AG Liposome preparation by single-pass process
JP5749494B2 (ja) 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション 核酸の送達のための改善された組成物および方法
JP5322476B2 (ja) 2008-03-31 2013-10-23 テルモ株式会社 リポソームの製造装置およびリポソームの製造方法
US8231787B2 (en) 2008-05-06 2012-07-31 Spf Innovations, Llc Tangential flow filtration system
EP2326331A4 (en) * 2008-08-18 2013-05-15 Merck Sharp & Dohme NOVEL LIPID NANOPARTICLES AND NEW COMPONENTS FOR NUCLEIC ACID ADMINISTRATION
SG196818A1 (en) 2008-10-16 2014-02-13 Marina Biotech Inc Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
CN102231952A (zh) * 2008-11-17 2011-11-02 安龙制药公司 用于核酸运载系统的可释放阳离子脂质
WO2010080724A1 (en) * 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
JP5684729B2 (ja) * 2009-01-20 2015-03-18 メッド コート エービーＭｅｄ Ｃｏａｔ Ａｂ 新規コーティング組成物とその使用
FR2943560B1 (fr) * 2009-03-24 2011-05-27 Jean Pascal Zambaux Bioreacteur jetable et systeme d'agitation a usage unique
EP2496700B1 (en) * 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
DK2506857T3 (en) * 2009-12-01 2018-05-07 Translate Bio Inc SUPPLY OF MRNA FOR AMPLIFICATION OF PROTEINS AND ENZYMES IN HUMAN GENETIC DISEASES
EP2526113B1 (en) * 2010-01-22 2016-08-10 Sirna Therapeutics, Inc. Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
WO2011127255A1 (en) 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Preparation of lipid nanoparticles
DK2998289T3 (da) * 2011-06-08 2019-09-16 Nitto Denko Corp Forbindelser til at målrette lægemiddellevering og fremme sirna-aktivitet

Also Published As

Publication number Publication date
JP6149041B2 (ja) 2017-06-14
US20130164400A1 (en) 2013-06-27
CA2853689A1 (en) 2013-06-27
KR20140097276A (ko) 2014-08-06
TWI615156B (zh) 2018-02-21
KR102056702B1 (ko) 2019-12-17
CN103906503B (zh) 2016-12-14
EP2773326A2 (en) 2014-09-10
JP6442551B2 (ja) 2018-12-19
CN103906503A (zh) 2014-07-02
RU2014122433A (ru) 2015-12-10
US8956572B2 (en) 2015-02-17
KR102046968B1 (ko) 2019-12-02
EP2773328A2 (en) 2014-09-10
TW201731491A (zh) 2017-09-16
WO2013093648A2 (en) 2013-06-27
LT2773326T (lt) 2019-04-25
TWI618548B (zh) 2018-03-21
EP3485875A1 (en) 2019-05-22
CN103906504A (zh) 2014-07-02
JP2014534232A (ja) 2014-12-18
WO2013093648A3 (en) 2013-10-24
HRP20190481T1 (hr) 2019-05-03
TW201325634A (zh) 2013-07-01
JP6133883B2 (ja) 2017-05-24
DK2773326T3 (en) 2019-04-15
WO2013064911A2 (en) 2013-05-10
AU2012330819B2 (en) 2017-08-31
HUE043809T2 (hu) 2019-09-30
CA2853685C (en) 2019-09-03
CA2853689C (en) 2020-06-30
JP2015502345A (ja) 2015-01-22
WO2013064911A3 (en) 2013-10-24
JP2017165748A (ja) 2017-09-21
SI2773326T1 (sl) 2019-04-30
ES2721325T3 (es) 2019-07-31
CA2853685A1 (en) 2013-05-10
EP2773326B1 (en) 2019-02-20
KR20140101748A (ko) 2014-08-20
CY1121495T1 (el) 2020-05-29
AU2012330819A1 (en) 2014-05-15
TR201904389T4 (tr) 2019-04-22
PT2773326T (pt) 2019-04-23
AU2012356239B2 (en) 2016-09-22
RU2014122432A (ru) 2015-12-10
AU2012356239A1 (en) 2014-05-29
RU2647476C2 (ru) 2018-03-15
EP3673898A1 (en) 2020-07-01
RU2642640C2 (ru) 2018-01-25
CN103906504B (zh) 2017-11-17
TWI626952B (zh) 2018-06-21
PL2773326T3 (pl) 2019-06-28
TW201323020A (zh) 2013-06-16

Similar Documents

Publication Publication Date Title
HRP20190481T1 (hr) Postupak za sterilnu pripravu nanočestica lipid-nukleinska kiselina
IL263389B (en) A method for the production of modified 5-fluoro-1h-pyrazolopyridines
ZA201401133B (en) Method for producing ternesite
EP2937329A4 (en) PROCESS FOR PRODUCING ACETIC ACID
IL231549A0 (en) A method for preparing glufosinate
PL2675539T3 (pl) Sposób wytwarzania poli(kwasu hydroksykarboksylowego)
SG2014005623A (en) Method for producing alpha-hydroxycarboxylic acid esters
ZA201304938B (en) Process for producing nitrile-fatty acid compounds
EP2735615A4 (en) PROCESS FOR PRODUCING ORGANIC ACID
PL2714589T3 (pl) Dwuwodzianowo-półwodzianowy sposób wytwarzania kwasu fosforowego
EP2784063A4 (en) PROCESS FOR THE PREPARATION OF BETA-MERCAPTOCARBONIC ACID
EP2857510A4 (en) PROCESS FOR PREPARING 3-ACETYLAMINO-4-HYDROXYBENZOIC ACID
EP2687515A4 (en) PROCESS FOR PREPARING A PYRAZOL CARBOXYLIC ACID DERIVATIVE
IL231877A0 (en) A method for the production of dithiene tetracarboximides
EP2796562A4 (en) METHOD FOR PRODUCING AN OPTICALLY ACTIVE SUBSTITUTED AMINO ACID
SG11201401916PA (en) Method for producing formic acid
EP2757089A4 (en) PROCESS FOR PRODUCING AMINO ACID
IL231878A0 (en) A method for the production of dithiene tetracarboximides
EP2784064A4 (en) PROCESS FOR PRODUCTION OF BETA-MERCAPTOCARBOXYLIC ACID